FDA Approves Bimekizumab for Adults with Plaque Psoriasis; The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

Press/Media

Period18 Oct 2023

Media coverage

2

Media coverage

  • TitleFDA Approves Bimekizumab for Adults with Plaque Psoriasis; The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.
    Media name/outletConsultant Live
    Country/TerritoryUnited States
    Date18/10/23
    PersonsMark Lebwohl
  • TitleFDA Approves Bimekizumab for Adults with Plaque Psoriasis
    Media name/outletHCP Live
    Country/TerritoryUnited States
    Date18/10/23
    PersonsMark Lebwohl